Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)

NCT02246218 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02246218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02246218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2014
Completion date
July 17, 2017
Enrollment
27 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

urea cycle disorder